10-12 April 2018
Boston, MA, USA

Press Releases

Norvartis Press Release TN

Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

Read it here.

Press Release TN Pursuing Larger Rivals

Pursuing Larger Rivals, NGM Bio Tries To Make Mark On Fatty Livers

Read it here.

Intercept jumps TN

Intercept jumps on NASH phase 3 protocol changes

Read it here.

Business wire 2 thumb

Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma

Read it here.

Fierce Biotech thumbnail

J&J in New Year deal mania, takes on NASH candidate with biotech buyout option

Read it here.

novartis-thumbnail

Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases

Read it here.

newswire-thumbnail

Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)

Read it here.

bristol-myers-quibb-press-release-thumb

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH

Read it here.

pr-newswire-thumb

TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data

Read it here.

healio-thumb

First patient dosed with MGL-3196 in NASH clinical trial

Read it here.

businesswire-thumb

Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)

Read it here.